• Home
  • Shiratori Pharmaceutical

Shiratori Pharmaceutical

About Shiratori Pharmaceutical

Shiratori Pharmaceutical is an API manufacturer in Japan focusing on APIs in niche markets such as rare diseases, rare oncology, neurology, etc. including high potency APIs. Manufacturing patents have been applied for Tafamidis and Eltrombopag in Japan.
Please find API pipeline below:
- Trametinib
- Cabazitaxel Acetonate
- Opicapone
- Ixazomib Citrate
- Brexpiprazole
- Valbenazine Tosilate
- Esaxerenone
- Pemafibrate
- Omidenepag
- Daprodustat- Macitentan
- Riociguat
- Selexipag
- Tafamidis

Read more Show less
Certifications
  • FDA
    FDA
  • GMP
    GMP
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Japan
  • On CPHI since:
    2020
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
CMO/CDMO
Distributor/Import Export
Generics/Biosimilars Manufacturer
Primary activities
API Producer
Contact info
  • +81-9046088039
  • JBSL Kanda Building 7F, 12 Kanda Higashi Matsushita, 101-0042, Chiyoda-ku, Tokyo-to, Japan
Show contact info Hide contact info
Meet us at

CPHI Milan 2026

Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
View Exhibitor Profile

Products from Shiratori Pharmaceutical (5)

  • Bortezomib

    Product Bortezomib

    Manufacturing technology can be transfered.
  • Brexpiprazole

    Product Brexpiprazole

    To be supplied to USA, EU and Japan.
  • Eltrombopag Olamine

    Product Eltrombopag Olamine

    Process validation is to be carried out soon.
  • Pemafibrate

    Product Pemafibrate

    To be supplied to USA, EU and Japan.
  • Tafamidis

    Product Tafamidis

    Process validation will be completed in early 2025.